FDA OK for India’s Marksans Pharma Generic Version of Type 2 Diabetes Drug
Read at
FDA OK for India’s Marksans Pharma Generic Version of Type 2 Diabetes Drug
SEE ALSO
Diabetes Drug: Latest Diabetes Drug News, Videos – NDTVprofit.ndtv.com/topic/diabetes–drug
| METFORMIN HYDROCHLORIDE ANDA (090295) | MARKSANS PHARMA | METFORMIN HYDROCHLORIDE |
| 500MG | TABLET, EXTENDED RELEASE;ORAL | 1 | 0 | AB1 |
| 750MG | TABLET, EXTENDED RELEASE;ORAL | 1 | 0 | AB |
Approval History
EARLIAR YEAR
METFORMIN HYDROCHLORIDE ANDA (090888)
| Strength | Form/Route | Marketing Status | RLD | TE Code |
|---|---|---|---|---|
| 500MG | TABLET;ORAL | 1 | 0 | AB |
| 850MG | TABLET;ORAL | 1 | 0 | AB |
| 1GM | TABLET;ORAL | 1 | 0 | AB |
Approval History
MR. MARK SALDANHA
Promoter And Managing Director
Mr. Mark Saldanha is the Chairman and Managing Director of Marksans. He set out with a vision to create a global pharmaceutical company. Under his able and dynamic leadership, Marksans has grown rapidly to attain newer milestones and the highest level of performance. He is the principal architect for the progress of the organization.
Mr. Mark Saldanha is a science graduate with more than two decades of experience across business and technical functions. He is well versed with the overall management of the company and possesses vast amount of hands-on experience in marketing, production and finance.
His business acumen, entrepreneurial zeal, organizational skills and managerial abilities have enabled Marksans to grow leaps and bounds and spread its wings across the globe.
////////Marksans Pharma, FDAm, ANDA, metformin hydrochloride, extended release (ER) tablets
